OmniAb Results Presentation Deck

● BCMA x CD3 ● ● Q4 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM AND PLATFORM VALUE TECVAYLI Ⓡ Janssen Sehusen-Jones US Marketing authorization granted for adult relapsed refractory multiple myeloma in October US launched in November OmniAb received $35 M in milestone payments related to TECVALI in January Reference: Partner and Company disclosures FcRn ● Batoclimab HANALL X BIOPHARMA HARBOUR BIDMED IMMUNOVANT Harbour announced positive topline results from Phase 3 trial in generalized Myasthenia Gravis in March Immunovant initiation of Phase 3 in thyroid eye disease and Phase 2b in chronic inflammatory demyelinating polyneuropathy PD-1 Zimberelimab gloria ARCUS BIOSCIENCES GILEAD Creating Possible Gilead Sciences and Arcus Biosciences announced positive results from the fourth interim analysis of the ARC-7 Phase 2 study in patients with first-line, metastatic NSCLC with PD- L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations PD-L1 ● ● Sugemalimab 基石药业 1381 QEQR CSTONE PHARMACEUTICALS Pfizer 10 EQRX announced acceptance of marketing authorization application in UK in December and EMA in Q1 CStone announced China's NMPA accepted supplementary NDA for sugemalimab in combination with chemo as first-line treatment of unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma OmniAb

View entire presentation